Page 96 - 《中国药房》2021年21期

regression analysis[J]. J Clin Epidemiol，1996，49（12）： rapy-induced nausea and vomiting：results from the pan
1373. European emesis registry study[J]. J Pain Symptom
[ 8 ] PEDUZZI P，CONCATO J，FEINSTEIN A R，et al. Impor- Manage，2016，51（6）：987-993.
tance of events per independent variable in proportional [18] MIR O，DURAND J P，BOUDOU-ROUQUETTE P，et al.
hazards regression analysis：Ⅱ ：accuracy and precision Interaction between serotonin reuptake inhibitors，5-HT3
of regression estimates[J]. J Clin Epidemiol，1995，48 antagonists，and NK1 antagonists in cancer patients recei-
（12）：1503. ving highly emetogenic chemotherapy：a case-control
[ 9 ] ZELLNER D，KELLER F，ZELLNER G E. Variable selec- study[J]. Support Care Cancer，2012，20（9）：2235-2239.
tion in logistic regression models[J]. Communications in [19] WARR D. Prognostic factors for chemotherapy induced
Statistics-Simulation and Computation，2004，33（3）：787- nausea and vomiting[J]. Eur J Pharmacol，2014，722：192-
805. 196.
[10] LEE S，SZABO S，GILMORE J，et al. Likelihood of a sub- [20] SHOJI A，TODA M，SUZUKI K，et al. Insufficient effec-
sequent chemotherapy-induced nausea and vomiting tiveness of 5-hydroxytryptamine-3 receptor antagonists
（CINV）event in patients receiving low，moderately or due to oral morphine administration in patients with cisp-
highly emetogenic chemotherapy （LEC/MEC/HEC）[J]. latin-induced emesis[J].J Clin Oncol，1999，17（6）：1926-
Curr Med Res Opin，2011，27（4）：837-845. 1930.
[11] CAPUTO R，CAZZANIGA M E，SBRANA A，et al. Netu- [21] TAKEI S，ISHIBE A，WATANABE J，et al. Risk factors of
pitant/palonosetron（NEPA）and dexamethasone for pre- chemotherapy-induced nausea and vomiting in patients
vention of emesis in breast cancer patients receiving adju- with metastatic colorectal cancer：a prospective cohort
vant anthracycline plus cyclophosphamide：a multi-cycle， study （YCOG1301）[J]. Int J Colorectal Dis，2020，35
phase Ⅱ study[J]. BMC Cancer，2020，20（1）：232. （12）：2323-2329.
[12] MOLASSIOTIS A，AAPRO M，DICATO M ，et al. Evalua- [22] KAWAZOE H，MURAKAMI A，YAMASHITA M，et al.
tion of risk factors predicting chemotherapy-related nau- Patient-related risk factors for nausea and vomiting with
sea and vomiting：results from a European prospective ob- standard antiemetics in patients with breast cancer recei-
servational study[J]. J Pain Symptom Manage，2014，47 ving anthracycline-based chemotherapy：a retrospective
（5）：839-848. observational study[J]. Clin Ther，2018，40（12）：2170-
[13] RITTMEISTER H，OSKAY-ÖZCELIK G，RICHTER R， 2179.
et al. Development of a questionnaire for monitoring risk [23] 周灵，左瑞玲，马莉，等.癌症患者化疗前焦虑对化疗后恶
factors for chemotherapy-induced nausea and vomiting：a 心呕吐的影响[J].昆明医科大学学报，2020，41（4）：142-
NOGGO pilot study[J]. Anticancer Res，2018，38（8）： 149.
4859-4864. [24] 陈心华，刘健，李娜妮，等.盐酸帕洛诺司琼预防高中度致
[14] MOSA A S M，HOSSAIN A M，LAVOIE B J，et al. Pa- 吐性化疗引起恶心呕吐的临床观察[J].临床药物治疗杂
tient-related risk factors for chemotherapy-induced nausea 志，2010，8（6）：45-48.
and vomiting：a systematic review[J]. Front Pharmacol， [25] TSUJI D，SUZUKI K，KAWASAKI Y，et al. Risk factors
2020，11：329. associated with chemotherapy-induced nausea and vomi-
[15] 高红飞，梁颖，周宁宁，等.盐酸帕诺洛司琼联合地塞米松 ting in the triplet antiemetic regimen including palonose-
预防顺铂化疗引起恶心和呕吐的临床观察[J].中华肿瘤 tron or granisetron for cisplatin-based chemotherapy：ana-
防治杂志，2012，19（9）：707-709. lysis of a randomized，double-blind controlled trial[J].
[16] PIRRI C，KATRIS P，TROTTER J，et al. Risk factors at Support Care Cancer，2019，27（3）：1139-1147.
pretreatment predicting treatment-induced nausea and [26] SEKINE I，SEGAWA Y，KUBOTA K，et al. Risk factors
vomiting in Australian cancer patients：a prospective，lon- of chemotherapy-induced nausea and vomiting：index for
gitudinal，observational study[J]. Support Care Cancer， personalized antiemetic prophylaxis[J]. Cancer Sci，2013，
2011，19（10）：1549-1563. 104（6）：711-717.
[17] MOLASSIOTIS A，LEE PH，BURKE T A，et al. Anticipa- （收稿日期：2020-12-22 修回日期：2021-05-12）
tory nausea，risk factors，and its impact on chemothe- （编辑：刘明伟）

·2646 · China Pharmacy 2021 Vol. 32 No. 21 中国药房 2021年第32卷第21期